Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katarina Slezakova"'
Autor:
Veronika Nemethova, Petra Mazancova, Boglarka Nemethova, Lucia Uhelska, Andrea Babelova, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova, Antonia Hatalova, Katarina Slezakova, Lubos Drgona, Iveta Oravcova, Eva Mikuskova, Ludmila Demitrovicova, Andrej Vranovsky, Filip Razga
Publikováno v:
Blood. 140:12995-12996
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4103202e3af5876c2ff2ae1a02969b35
https://doi.org/10.1182/blood-2022-166148
https://doi.org/10.1182/blood-2022-166148
Publikováno v:
Vnitřní lékařství. 66:214-224
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia that is characterised by Philadelphia chromosome (Ph1 chromosome) and/or fusion gene BCR-ABL1 in bone marrow. Interpheron#945; and bone marrow transplantation used to be the main
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfbbdbbb737d8c1b98778372e83ba91
https://doi.org/10.36290/vnl.2020.064
https://doi.org/10.36290/vnl.2020.064
This position paper reflects on the potential implementation of a certification system for the quality of gender equality training in the field of research and innovation. Gender equality training and, more generally, gender equality capacity-buildin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b7de55ea6c05236a8657a5d96cd006
Autor:
Vaclav Horejsi, Samuel Godar, Vladimir Leksa, Arshad Muhammad, Peter Steinlein, Bernd R. Binder, Hannes Stockinger, Katarina Slezakova, Herbert B. Schiller, Ulrich H. Weidle, Elke Fuertbauer
Publikováno v:
Journal of Cell Science. 118:4577-4586
Transforming growth factor-beta (TGF-beta), a key modulator of endothelial cell apoptosis, must be activated from the latent form (LTGF-beta) to induce biological responses. In the present study, we report activation of TGF-beta by functional and phy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ce78926cba54c7b88f41ed046c437f
https://doi.org/10.1242/jcs.02587
https://doi.org/10.1242/jcs.02587
Autor:
Ludmila Demitrovicova, Jana Lesko-Andrascikova, Adriana Kafková, Zuzana Sninská, Eva Mikuskova, Martin Mistrik, Tereza Nečasová, Stanislav Palasthy, Katarina Slezakova, Juraj Chudej, Eva Koritakova, Imrich Markuljak, Natalia Stecova, Elena Tóthová
Publikováno v:
ResearcherID
Introduction: With the onset of tyrosine kinase inhibitors (TKI) to treat patients with CML, the number of patients and overall survival increased and quality of life significantly improved. The basic principle of therapy was also changed, according
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb741c467c20df0c93539a7c8f0a9f06
https://doi.org/10.1182/blood.v128.22.3087.3087
https://doi.org/10.1182/blood.v128.22.3087.3087